The present invention relates to antisense oligonucleotide (ASO) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (ASOs). Hybrid ASOs, part single-stranded and part double-stranded, are provided, hybridising to form a double-stranded region that can non-covalently bond to nucleic-acid-binding protein regions. In this way, ASO::protein complexes may be produced that facilitate delivery of antisense DNA into target cells. Such complexes may be used to down-regulate gene expression in cells
The clinical application of antisense oligonucleotides (ASOs) is becoming more of a reality as sever...
Antisense oligonucleotides efficiently inhibit gene expression in vitro; however, the successful the...
The efficacy of traditional anti-cancer agents is hampered by toxicity to normal tissues, due to the...
Antisense oligonucleotides (ASOs), which are synthetic single-stranded nucleic acids, could enter li...
Atypical gene expression has a major influence on the disease profile of several severe human disord...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
Nucleic acid-based therapeutics have demonstrated their efficacy in the treatment of various disease...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
International audienceThe cytokine network is involved in normal immune reaction and in the progress...
The clinical application of antisense oligonucleotides (ASOs) is becoming more of a reality as sever...
The subject invention concerns a method of inhibiting an RNA virus infection within a patient by inc...
Abstract: Antisense oligonucleotides (As-ODNs) are single stranded, synthetically prepared strands o...
Antisense oligonucleotides were potentially very powerful tools to modulate gene expression. Progres...
The clinical application of antisense oligonucleotides (ASOs) is becoming more of a reality as sever...
Antisense oligonucleotides efficiently inhibit gene expression in vitro; however, the successful the...
The efficacy of traditional anti-cancer agents is hampered by toxicity to normal tissues, due to the...
Antisense oligonucleotides (ASOs), which are synthetic single-stranded nucleic acids, could enter li...
Atypical gene expression has a major influence on the disease profile of several severe human disord...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
Nucleic acid-based therapeutics have demonstrated their efficacy in the treatment of various disease...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selecti...
International audienceThe cytokine network is involved in normal immune reaction and in the progress...
The clinical application of antisense oligonucleotides (ASOs) is becoming more of a reality as sever...
The subject invention concerns a method of inhibiting an RNA virus infection within a patient by inc...
Abstract: Antisense oligonucleotides (As-ODNs) are single stranded, synthetically prepared strands o...
Antisense oligonucleotides were potentially very powerful tools to modulate gene expression. Progres...
The clinical application of antisense oligonucleotides (ASOs) is becoming more of a reality as sever...
Antisense oligonucleotides efficiently inhibit gene expression in vitro; however, the successful the...
The efficacy of traditional anti-cancer agents is hampered by toxicity to normal tissues, due to the...